PT  - JOURNAL ARTICLE
AU  - Hu, Wanling
AU  - Liu, Xiaoyun
AU  - Wang, Tao
AU  - Zhou, Changlong
AU  - Liu, Dingfu
AU  - Zhang, Yuanming
AU  - Hu, Zhongli
AU  - Diao, Ying
TI  - Estimation of COVID-19 case fatality ratio based on a bi-directional correction method
AID  - 10.1101/2020.05.02.20089144
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.02.20089144
4099  - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20089144.short
4100  - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20089144.full
AB  - The case fatality rate (CFR) can be used to predict the number of potential deaths in the epidemic and thus can reflect the appropriateness and quality of medical measures developed by public health. When a new disease breaks out, it is particularly important to accurately estimate the CFR. However, while the epidemic is still developing, the crude CFR is often lower than the true value and the hospital CFR is often higher than the true value due to differences in occurrence time, patient number, and treatment plans. Therefore, this study proposes a bi-directional correction method to estimate the CFR. COVID-19 data from China were used to evaluate this method. The results show that this method provides more accurate results than both the crude CFR and hospital CFR. Additionally, this method was used to estimate the CFR of COVID-19 in other countries, with an aim to provide a reference for prevention and control decisions for the COVID-19 epidemic and for the evaluation of medical efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of all data in the manuscript are list in the tables and supplementary tables.